组织诊断市场规模、份额和成长分析（按产品类型、技术、疾病类型、检测方法、最终用户和地区划分）－2026-2033年产业预测

全球组织诊断市场规模预计在 2024 年达到 56 亿美元，从 2025 年的 60.7 亿美元成长到 2033 年的 115.7 亿美元，在预测期（2026-2033 年）内复合年增长率为 8.4%。

受癌症发病率上升和医疗环境变化的推动，全球组织诊断市场预计将迎来显着成长。儘管疫情导致资源重新分配，暂时阻碍了诊断检测，但随着医疗系统的调整，对精准诊断服务的需求激增。这种需求的復苏凸显了对各种疾病（尤其是癌症）进行精确监测的迫切需求。此外，随着解剖病理学和分子病理学的融合日益加深以及液态生物检体的加速应用，该行业正在经历重组。对计算病理学的日益重视，强调生物资讯学和分析技术的整合，正在推动创新。过去二十年来，先进仪器的进步彻底改变了病理学家和临床医生的能力，进一步推动了临床病理学领域的扩张。

全球组织诊断市场驱动因素

组织诊断市场的关键成长要素是慢性疾病（尤其是癌症）发生率的上升。随着全球癌症发病率的持续增长，对快速、准确的诊断解决方案的需求至关重要，因为早期发现是治疗效果的关键。免疫组织化学和分子病理学等组织诊断技术的创新使医疗专业人员能够准确识别肿瘤类型和亚型。对可靠诊断工具日益增长的需求促使医疗机构投资于先进的组织诊断技术。这一趋势不仅推动了市场成长，也有助于提高癌症患者的医疗服务品质。

限制全球组织诊断市场的因素

全球组织诊断市场面临的主要挑战之一是现代诊断技术的高成本。先进的工具和调查方法往往伴随着沉重的经济负担，使得小规模医院和检查室难以负担。设备购置、人员培训和持续维护等相关费用进一步加剧了这个问题，尤其是在医疗资源有限的地区。因此，高成本阻碍了创新诊断解决方案的普及，尤其是在发展中地区，这限制了患者获得准确诊断工具的机会，并阻碍了整个组织诊断市场的成长。

全球组织诊断市场趋势

全球组织诊断市场正经历着向个人化医疗的重大转变，其驱动力在于对根据个别患者情况量身定制的精准治疗的需求。这一趋势也受到对能够识别与各种疾病和肿瘤相关的特定生物标记的先进诊断工具的需求不断增长的推动。随着医疗专业人员越来越重视基于基因和分子资讯的个人化治疗方案，基因谱分析和分子诊断技术的创新在实现个人化医疗方面发挥关键作用。由此产生的对客製化医疗的关注正在推动组织诊断技术的进步，为患者提供更有效、更有针对性的治疗选择。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管环境
• 案例研究
• 技术分析

全球组织诊断市场规模（按产品类型和复合年增长率划分）（2026-2033 年）

• 消耗品
  • 抗体
  • 成套工具
  • 试剂
  • 探测
• 装置
  • 玻片染色系统
  • 扫描器
  • 组织处理系统
  • 其他设备

全球组织诊断市场规模（依技术及复合年增长率划分）（2026-2033 年）

• 免疫组织化学
• 原位杂合反应
• 初级染色和特殊染色
• 组织病理学
• 分子病理学
• 数位病理学和工作流程管理
• 特殊染色

全球组织诊断市场规模（按疾病类型和复合年增长率划分）（2026-2033 年）

• 乳癌
• 胃癌
• 淋巴瘤
• 摄护腺癌
• 非小细胞肺癌
• 其他的

全球组织诊断市场规模（依诊断方式及复合年增长率划分）（2026-2033 年）

• 临床
• 製药/合约研究组织/研究市场

全球组织诊断市场规模（按最终用户和复合年增长率划分）（2026-2033 年）

• 医院
• 研究所
• 製药公司
• 合约研究组织（CRO）
• 其他的

全球组织诊断市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• F. Hoffmann-La Roche Ltd.（Switzerland）
• Abbott Laboratories（USA）
• Thermo Fisher Scientific Inc.（USA）
• Siemens Healthineers（Germany）
• Danaher Corporation（USA）
• bioMerieux SA（France）
• QIAGEN NV（Netherlands）
• Becton, Dickinson and Company（BD）（USA）
• Merck KGaA（Germany）
• GE Healthcare（USA）
• BioGenex Laboratories（USA）
• Cell Signaling Technology, Inc.（USA）
• Bio SB（USA）
• DiaGenic ASA（Norway）
• Agilent Technologies（USA）
• Fujirebio Inc.（Japan）
• Tecan Group Ltd.（Switzerland）
• STRATEC SE（Germany）
• Seegene Inc.（South Korea）
• Leica Biosystems（Germany）

结论与建议

Global Tissue Diagnostics Market size was valued at USD 5.60 Billion in 2024 and is poised to grow from USD 6.07 Billion in 2025 to USD 11.57 Billion by 2033, growing at a CAGR of 8.4% during the forecast period (2026-2033).

The global tissue diagnostics market is poised for significant growth, driven by the rising incidence of cancer and an evolving healthcare landscape. The pandemic temporarily hindered diagnostic testing due to resource reallocation, but as healthcare systems adapted, demand for precise diagnostic services surged. This resurgence highlights the urgent need for accurate monitoring of various diseases, particularly cancer. Furthermore, the convergence of anatomic and molecular pathology is reshaping the industry, with liquid biopsies becoming more prevalent. The increasing focus on computational pathology emphasizes the integration of bioinformatics and analytics, fostering innovation. Over two decades, advancements in sophisticated equipment have revolutionized the capabilities of pathologists and clinical practitioners, further propelling the expansion of the clinical pathology domain.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Tissue Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Tissue Diagnostics Market Segments Analysis

Global Tissue Diagnostics Market is segmented by Product Type, Technology, Disease Type, Modality, End-user and region. Based on Product Type, the market is segmented into Consumables and Instruments. Based on Technology, the market is segmented into Immunohistochemistry, In Situ Hybridization, Primary & Special Staining, Anatomic Pathology, Molecular Pathology, Digital Pathology & Workflow Management and Special Staining. Based on Disease Type, the market is segmented into Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-small Cell Lung Cancer and Others. Based on Modality, the market is segmented into Clinical and Pharma / CRO / Research Market. Based on End-user, the market is segmented into Hospitals, Research Laboratories, Pharmaceutical Companies, Contract Research Organizations (CROs) and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Tissue Diagnostics Market

A significant growth catalyst for the tissue diagnostics market is the rising incidence of chronic diseases, particularly cancer. As global cancer rates continue to escalate, the demand for swift and precise diagnostic solutions becomes crucial, as early detection is key to successful treatment outcomes. Innovations in tissue diagnostics, such as immunohistochemistry and molecular pathology, empower healthcare professionals to accurately identify tumor types and subtypes. The mounting need for reliable diagnostic tools is motivating healthcare providers to invest in advanced tissue diagnostic technologies. This trend not only propels market growth but also enhances the quality of care available to cancer patients.

Restraints in the Global Tissue Diagnostics Market

One significant challenge facing the Global Tissue Diagnostics market is the high cost associated with modern diagnostic techniques. Advanced tools and methodologies often come with substantial financial burdens, making them inaccessible for smaller hospitals and laboratories. The expenses related to equipment acquisition, staff training, and ongoing maintenance further exacerbate this issue, particularly in regions with limited healthcare resources. As a result, the high costs can hinder the adoption of innovative diagnostic solutions, especially in developing areas, which in turn restricts patient access to accurate diagnostic tools and ultimately stifles growth within the overall market for tissue diagnostics.

Market Trends of the Global Tissue Diagnostics Market

The Global Tissue Diagnostics market is experiencing a significant shift towards personalized healthcare, driven by the need for precision therapies that cater to individual patient profiles. This trend is bolstered by the increasing demand for advanced diagnostic tools capable of identifying specific biomarkers linked to various diseases and tumors. As medical professionals increasingly prioritize tailored treatment plans based on genetic and molecular insights, innovations in genetic profiling and molecular diagnostics are playing a crucial role in enabling these personalized approaches. Consequently, this focus on customized healthcare is fueling advancements in tissue diagnostics technology, paving the way for more effective and targeted therapeutic options for patients.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technology Analysis

Global Tissue Diagnostics Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Consumables
  • Antibodies
  • Kits
  • Reagents
  • Probes
• Instruments
  • Slide-staining Systems
  • Scanners
  • Tissue-processing Systems
  • Other Instruments

Global Tissue Diagnostics Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Immunohistochemistry
• In Situ Hybridization
• Primary & Special Staining
• Anatomic Pathology
• Molecular Pathology
• Digital Pathology & Workflow Management
• Special Staining

Global Tissue Diagnostics Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Breast Cancer
• Gastric Cancer
• Lymphoma
• Prostate Cancer
• Non-small Cell Lung Cancer
• Others

Global Tissue Diagnostics Market Size by Modality & CAGR (2026-2033)

• Market Overview
• Clinical
• Pharma / CRO / Research Market

Global Tissue Diagnostics Market Size by End-user & CAGR (2026-2033)

• Market Overview
• Hospitals
• Research Laboratories
• Pharmaceutical Companies
• Contract Research Organizations (CROs)
• Others

Global Tissue Diagnostics Market Size & CAGR (2026-2033)

• North America (Product Type, Technology, Disease Type, Modality, End-user)
  • US
  • Canada
• Europe (Product Type, Technology, Disease Type, Modality, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Technology, Disease Type, Modality, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Technology, Disease Type, Modality, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Technology, Disease Type, Modality, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioGenex Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cell Signaling Technology, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio SB (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DiaGenic ASA (Norway)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujirebio Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tecan Group Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• STRATEC SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seegene Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Leica Biosystems (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations